Comparing cryoablation and medical therapy for desmoid tumors after watchful waiting
A Phase II Multicentric, Randomized Trial Assessing Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
This study is testing whether cryoablation works better than medical therapy for people with desmoid tumors that have gotten worse after watching them for a while.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 13 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | methotrexate, chemotherapy |
| Locations | 13 sites (Besançon and 12 other locations) |
| Trial ID | NCT06081400 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of cryoablation compared to medical therapy in patients with desmoid tumors that have progressed after a period of watchful waiting. The study will involve a randomized design, allowing participants to receive either treatment, with a cross-over option to ensure all patients can access cryoablation if needed. Eligible patients must have measurable tumors and demonstrate progressive disease or significant symptoms. The trial is designed to provide insights into the best management strategies for desmoid tumors.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 13 and older with extra-peritoneal desmoid tumors that have shown progression after watchful waiting.
Not a fit: Patients with stable desmoid tumors who do not require active treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a more effective treatment option for patients with progressive desmoid tumors, potentially improving their quality of life.
How similar studies have performed: While cryoablation has shown promise in treating desmoid tumors, this specific comparison with medical therapy is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject (male or female) with extra-peritoneal desmoid tumor (confirmed by prior biopsy by an experienced pathologist within the RRePS network) * 13 years of age or older * Measurable viable tumor (according to the mRECIST criteria using MRI. The baseline MRI imaging is mandatory in the 2 months prior to treatment initiation (D0). * Progressive disease (according to the mRECIST criteria) after the watchful waiting period or significant increase in symptoms requiring an active therapy, as advised in a multidisciplinary sarcoma tumor board * Tumor deemed accessible for cryoablation procedure by the operator in a type I center. (In pediatric cases, a careful site tumor analysis will be performed with interventional radiologist to ensure for limited consequence of cryoablation in pediatric patients especially regarding growth plates). * 100 % of destruction of the tumor achievable in one procedure of cryoablation with 1cm security margin according to assessment by referral center (type 1) for cryoablation * ECOG performance status 0-2 at inclusion visit * Biological and hematological parameters (neutrophils ≥ 1,5.109/L ; platelet count ≥ 100.109/L ; no significant hemostatic abnormalities) in the 4 weeks prior to treatment initiation (D0) * Subject able to understand the objectives and risks of the research and to give dated and signed informed consent. For minors, the consent of the 2 parents must be obtained. * Subject affiliated to a social health insurance plan * For a woman of childbearing age: negative blood pregnancy test at screening/inclusion visit * Subject agreeing to use a contraceptive method Exclusion criteria: * Intra-peritoneal or multifocal desmoid tumor * Concurrent or prior use of any antitumor agent for the current desmoid tumor * Relapse after surgery for desmoid tumor * Any contraindication including known hypersensitivity to vinorelbine or other vinca-alkaloids, or other constituents to navelbine, to vinblastine, to methotrexate or any excipients, such as, but not limited to current or recent (within 2 weeks) severe infection, severe renal failure, severe hepatic injury, chronic respiratory failure * Any contraindication including hypersensitivity to gadoteric acid, meglumine or any drug containing gadolinium * Concomitant treatment with: yellow fever vaccine, prophylactic treatment with phenytoin, trimethoprim, ciprofloxacin, penicillins, probenecid, acetylsalicylic acid, NSAIDs, PPIs, acitretin, azote protoxide, St John's wort * Any contra-indication for the procedure as stated by the interventional radiologist in terms of tumor size, proximity to neural/vascular structures or adjacent organs at risk making the procedure at unacceptable risk * Impaired hemostasis, that may interfere with the conduct of the cryoablation * Contraindication to any form of sedation * Others contra-indications to MRI * Pregnancy or breastfeeding * Concurrent participation in other experimental studies that could affect endpoints of the present study * Impossibility to give the subject informed information (subject in an emergency situation, patient with comprehension difficulties ...) * Psychiatric disorders * Incompetent subject (subject to a legal protection measure: curatorship, guardianship, future protection mandate, family habilitation)
Where this trial is running
Besançon and 12 other locations
- Service d'oncologie/CHU de Besançon — Besançon, France (Not_yet_recruiting)
- Service d'Oncologie Médicale, Service de Radiologie Interventionnelle, Institut BERGONNIE — Bordeaux, France (Recruiting)
- Service d'Oncologie Médicale, Service de Radiologie Interventionnelle-Centre François BACLESSE — Caen, France (Recruiting)
- Service d'Oncologie Médicale -Centre Georges François LECLERC — Dijon, France (Recruiting)
- Service d'Oncologie Médicale, Service de Radiologie Interventionnelle-Centre Léon BERARD — Lyon, France (Recruiting)
- Service d'Oncologie Médicale, service de Radiologie Interventionnelle,CHU de Marseille, Hopital La Timone — Marseille, France (Recruiting)
- Service de Radiologie-CHU de Nantes — Nantes, France (Recruiting)
- Service d'Oncologie Médicale-Centre Antoine LACASSAGNE — Nice, France (Recruiting)
- Service d'Oncologie Médicale — Saint-Herblain, France (Recruiting)
- Institut de cancérologie Strasbourg Europe (ICANS) — Strasbourg, France (Recruiting)
- Service d'Imagerie Interventionnelle, Hôpitaux Universitaires de Strasbourg , France, 67091 — Strasbourg, France (Recruiting)
- Service d'Oncologie Médicale-Institut Claudius Régaud et Service de Radiologie Interventionnelle, CHU de Toulouse — Toulouse, France (Not_yet_recruiting)
- Service d'Oncologie médicale, Service de Radiologie Interventionnelle- Institut Gustave ROUSSY — Villejuif, France (Recruiting)
Study contacts
- Principal investigator: Afshin GANGI, MD, PhD — Hôpitaux Universitaires de Strasbourg
- Study coordinator: Afshin GANGI, MD,PhD
- Email: afshin.gangi@chru-strasbourg.fr
- Phone: 0369550304
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.